Biotech Values

[turtlepower]

ACHN - I looked at the slides for the presentation outlining their goals for the rest of the year and I don't see any clinical trials for compounds other than 1625. I'm curious what they will spend their money on (other than 1625) assuming they partner and get a decent upfront payment. Or are those objectives based on no partnerships?

Any thoughts on ACHN valuation compared to IDIX? Based on todays price the EV for ACHN is about 75 M while IDIX is around 150 M. IDIX is slightly further along in its HCV pipeline though.

Regarding partnership, i was surprised to see (thanks to Dew's list of hcv partnerships) that zgen had landed a partnership with a pretty significant upfront payment considering the development stage of its compound, as well as other similar partnerships. I was already aware of ITMN's deal and assumed ACHN would receive a deal that would not be as good as ITMN's considering that there is a lot of competition since the ITMN deal was struck, but after seeing the ZGEN deal I'm not sure.